Bifeprunox: beneficial in schizophrenia?

Author：  

Publisher： Adis International

ISSN： 1173-8324

Source： Inpharma, Vol.1, Iss.1570, 2007-01, pp. : 9-10

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Predictor of treatment response in schizophrenia?

By  

Inpharma, Vol. 1, Iss. 1280, 2001-01 ,pp. : 18-18

Adis International

Access to resources Recommend Favorite

Atypical antipsychotics cause diabetes mellitus in schizophrenia?

By  

Inpharma, Vol. 1, Iss. 1289, 2001-01 ,pp. : 20-20

Adis International

Access to resources Recommend Favorite

Does Olanzapine Warrant Clinical Pharmacokinetic Monitoring in Schizophrenia?

By Schwenger Erin   Dumontet Jane   Ensom Mary H.H.  

Clinical Pharmacokinetics, Vol. 50, Iss. 7, 2011-07 ,pp. : 415-428

Adis International

Access to resources Recommend Favorite

Do QOL scores reflect therapy in schizophrenia?

By  

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 310, 2001-01 ,pp. : 10-10

Adis International

Access to resources Recommend Favorite

Do Acetylcholinesterase Inhibitors Have a Role in Improving Cognitive Impairment in Patients with Schizophrenia?

By Alessandro Lenzi   Daniela Tuscano  

International Journal of Pharmaceutical Medicine, Vol. 18, Iss. 3, 2004-01 ,pp. : 139-148

Adis International

Access to resources Recommend Favorite